HolderBook

Kynam Capital Management, LP

Reported holdings as of Q2 2026, from 19 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1907884
Reported value
$1.8B
Positions
32
Top 10 weight
72.7%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
CELLDEX THERAPEUTICS INC NEWCLDX$198.1M5,322,90810.95%-0.48pp19q-8.9%-$19.3M
SYNDAX PHARMACEUTICALS INCSNDX$176.0M8,050,9599.73%-1.87pp19qHELD
VAXCYTE INCPCVX$169.9M2,922,3359.39%-1.09pp19qHELD
COGENT BIOSCIENCES INCCOGT$141.9M3,667,0977.84%-1.74pp17q-9.2%-$14.3M
VERA THERAPEUTICS INCVERA$124.0M2,890,0596.85%-1.58pp19q-15.0%-$21.8M
VIRIDIAN THERAPEUTICS INCVRDN$118.6M6,453,8776.55%+3.73pp19q+175.6%+$75.5M
TRAVERE THERAPEUTICS INCTVTX$113.6M2,000,0006.28%+1.84pp19q+27.5%+$24.5M
BEAM THERAPEUTICS INCBEAM$97.5M2,840,7925.39%-0.02pp8q-22.9%-$28.9M
UROGEN PHARMA LTDURGN$89.6M2,434,2074.95%+2.46pp2q+8.3%+$6.9M
LEGEND BIOTECH CORPLEGN$86.7M3,001,2054.79%+3.03pp2q+90.4%+$41.2M
CYTOMX THERAPEUTICS INCCTMX$81.4M21,703,0934.50%+0.15pp5q+44.6%+$25.1M
RELAY THERAPEUTICS INCRLAY$61.7M3,300,0003.41%+2.54pp7q+131.7%+$35.1M
CULLINAN THERAPEUTICS INCCGEM$56.7M3,114,1323.13%+0.40pp7qHELD
MBX BIOSCIENCES INCMBX$51.6M934,7992.85%+1.13pp4qHELD
IMMUNOCORE HLDGS PLCIMCR$43.7M1,375,0002.41%+0.77pp7q+55.4%+$15.6M
NURIX THERAPEUTICS INCNRIX$29.0M1,194,7571.60%+0.46pp6qHELD
SUTRO BIOPHARMA INCSTRO$29.0M872,5581.60%+0.26pp3qHELD
BIOCRYST PHARMACEUTICALS INCBCRX$25.2M2,522,6601.39%-1.94pp14q-55.6%-$31.6M
PHARVARIS N VPHVS$22.9M661,7951.26%+0.15pp4q+3.3%+$740.0K
SUMMIT THERAPEUTICS INCSMMT$17.5M1,200,0000.97%-newNEW
PRELUDE THERAPEUTICS INCPRLD$12.9M2,415,0870.71%+0.38pp3q+51.6%+$4.4M
INSMED INCINSM$10.7M100,0000.59%-newNEW
BURNING ROCK BIOTECH LTDBNR$10.5M1,238,5630.58%-0.64pp9q+0.9%+$93.5K
GERON CORPGERN$8.8M6,836,3180.48%-0.14pp6qHELD
AMARIN CORP PLCAMRN$8.5M532,9820.47%+0.05pp5q+12.8%+$966.0K
ALECTOR INCALEC$7.7M3,808,4940.42%+0.16pp3q+90.4%+$3.6M
PARABILIS MEDICINES INCPBLS$6.8M250,0000.38%-newNEW
CARIBOU BIOSCIENCES INCCRBU$4.4M2,503,3020.24%-0.05pp12qHELD
PROQR THRAPEUTICS N VPRQR$2.9M1,566,3170.16%flat7qHELD
CANDEL THERAPEUTICS INCCADL$996.4K96,7410.06%-0.01pp2q-51.6%-$1.1M
Engene Therapeutics IncENGN$792.1K457,8550.04%-newNEW
TRAWS PHARMA INCTRAW$71.2K84,4000.00%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 99.0%Other sectors 0.6%Not classified 0.4%
 
SectorValueShare
Biotech & Pharma$1.8B99.0%
Other sectors$10.5M0.6%
Not classified$6.8M0.4%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+14.9%+14.8%+0.0%93%
Q1 2026+6.8%-4.6%+11.4%97%
Q4 2025+49.4%+2.4%+47.1%101%
Q3 2025+35.0%+7.8%+27.2%100%
Q2 2025+0.3%+10.5%-10.2%100%
Q1 2025-20.2%-4.6%-15.6%100%
Q4 2024-5.4%+2.1%-7.5%100%
Q3 2024+15.4%+5.4%+10.0%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$1.8B3251261072.7%45
Q1 2026$1.6B375129471.9%45
Q4 2025$1.6B366422573.5%48
Q3 2025$1.3B35574172.6%45
Q2 2025$928.8M313421477.4%45
Q1 2025$1.2B326144472.7%45
Q4 2024$1.7B306135176.1%45
Q3 2024$1.3B252173381.5%45
Q2 2024$1.3B265172281.9%45
Q1 2024$955.5M23258381.0%45
Q4 2023$902.6M244105878.4%45
Q3 2023$611.4M28794582.8%45
Q2 2023$727.1M2621061182.7%45
Q1 2023$774.6M3581213477.3%45
Q4 2022$651.9M315105981.1%45
Q3 2022$474.6M3561117473.4%45
Q2 2022$391.6M3351611579.2%46
Q1 2022$308.3M3351314376.2%43
Q4 2021$187.1M31000068.6%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.